BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflamm Bowel Dis 2019;25:385-93. [PMID: 30169584 DOI: 10.1093/ibd/izy240] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Tian Y, Abu-sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Colitis. In: Naing A, Hajjar J, editors. Immunotherapy. Cham: Springer International Publishing; 2018. pp. 151-7. [DOI: 10.1007/978-3-030-02505-2_7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
2 Yin J, Elias R, Peng L, Levonyak N, Asokan A, Christie A, Kubiliun N, Brugarolas J, Hammers HJ. Chronic use of proton pump inhibitors is associated with an increased risk of immune checkpoint inhibitor colitis in renal cell carcinoma. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.01.017] [Reference Citation Analysis]
3 Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142. [PMID: 30518410 DOI: 10.1186/s40425-018-0461-4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
4 Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115:202-210. [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
5 Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier R, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favourable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93. [PMID: 30940209 DOI: 10.1186/s40425-019-0577-1] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 19.7] [Reference Citation Analysis]
6 Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol 2019;42:789-96. [PMID: 31478934 DOI: 10.1097/COC.0000000000000596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, Sullivan RJ, Dougan M. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292. [PMID: 31699151 DOI: 10.1186/s40425-019-0756-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
8 Abu-Sbeih H, Wang Y. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26:662-668. [PMID: 31560045 DOI: 10.1093/ibd/izz212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
9 Isidro RA, Ruan AB, Gannarapu S, Raj D, Rahma O, Grover S, Srivastava A. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021;78:532-41. [PMID: 32931028 DOI: 10.1111/his.14248] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Gallo A, Talerico R, Novello L, Giustiniani MC, D'Argento E, Bria E, Montalto M. Collagenous colitis and atezolizumab therapy: an atypical case. Clin J Gastroenterol 2021;14:165-9. [PMID: 33151423 DOI: 10.1007/s12328-020-01276-4] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Reference Citation Analysis]
12 Favara DM, Zois CE, Haider S, Pires E, Sheldon H, McCullagh J, Banham AH, Harris AL. ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile. Metabolites 2019;9:E287. [PMID: 31775252 DOI: 10.3390/metabo9120287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, Chauhan D, Turajlic S, Powell N, Larkin JM, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open. 2020;5. [PMID: 32641348 DOI: 10.1136/esmoopen-2019-000585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ma C, Pai RK, Schaeffer DF, Krell J, Guizzetti L, McFarlane SC, MacDonald JK, Choi WT, Feakins RM, Kirsch R, Lauwers GY, Pai RK, Rosty C, Srivastava A, Walsh JC, Feagan BG, Jairath V. Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. J Immunother Cancer 2022;10:e004560. [PMID: 35296560 DOI: 10.1136/jitc-2022-004560] [Reference Citation Analysis]
15 de Andrea CE, Perez-Gracia JL, Castanon E, Ponz-Sarvise M, Echeveste JI, Melero I, Sanmamed MF, Rodriguez-Ruiz ME. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. Oncoimmunology 2020;9:1760676. [PMID: 32934876 DOI: 10.1080/2162402X.2020.1760676] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Mallepally N, Abu-Sbeih H, Ahmed O, Chen E, Shafi MA, Neelapu SS, Wang Y. Clinical Features of Rituximab-associated Gastrointestinal Toxicities. Am J Clin Oncol 2019;42:539-45. [PMID: 31136371 DOI: 10.1097/COC.0000000000000553] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology (Oxford) 2019;58:vii17-28. [PMID: 31816081 DOI: 10.1093/rheumatology/kez465] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
18 Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 2019;7:118. [PMID: 31053161 DOI: 10.1186/s40425-019-0604-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
19 Vaziri H, Turshudzhyan A, Vecchio E. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan. J Clin Gastroenterol 2022. [PMID: 35470301 DOI: 10.1097/MCG.0000000000001705] [Reference Citation Analysis]
20 Chen E, Abu-Sbeih H, Thirumurthi S, Mallepally N, Khurana S, Wei D, Altan M, Morris VK, Tan D, Barcenas CH, Wang Y. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol 2020;33:59-67. [PMID: 31892799 DOI: 10.20524/aog.2019.0431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, Lo S, Carlino M, Palendira U, Scolyer RA, Long GV, Menzies AM. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. J Immunother Cancer 2020;8:e001488. [PMID: 33234603 DOI: 10.1136/jitc-2020-001488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gong Z, Wang Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract 2020;16:453-61. [PMID: 32584703 DOI: 10.1200/OP.20.00002] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Abu-Sbeih H, Wang Y. Gastrointestinal Tract Adverse Events. Adv Exp Med Biol 2020;1244:247-53. [PMID: 32301019 DOI: 10.1007/978-3-030-41008-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Thomas AS, Wang Y. Immunotherapy-Mediated Luminal Gastrointestinal Toxicities. Adv Exp Med Biol 2021;1342:331-7. [PMID: 34972972 DOI: 10.1007/978-3-030-79308-1_12] [Reference Citation Analysis]
25 De Silva S, Trieu H, Rajan A, Liang Y, Lin JL, Kidambi TD. Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy-mediated colitis: A cross-sectional study. J Gastroenterol Hepatol 2021. [PMID: 34547818 DOI: 10.1111/jgh.15691] [Reference Citation Analysis]
26 Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:1393-1403.e1. [PMID: 32007539 DOI: 10.1016/j.cgh.2020.01.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
27 Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019;37:2738-2745. [PMID: 31163011 DOI: 10.1200/jco.19.00320] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 14.3] [Reference Citation Analysis]
28 Rajha E, Chaftari P, Kamal M, Maamari J, Chaftari C, Yeung SJ. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol Rep (Oxf) 2020;8:25-30. [PMID: 32104583 DOI: 10.1093/gastro/goz065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, Richards DM, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54:538-545. [PMID: 31079556 DOI: 10.1080/00365521.2019.1594356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
30 Ibraheim H, Green M, Papa S, Powell N. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. BMJ Case Rep 2019;12:e226481. [PMID: 30948391 DOI: 10.1136/bcr-2018-226481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Zengin ZB, Salgia NJ, Chehrazi-Raffle A, Meza L, Malhotra J, Pal SK. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. Cancer J 2020;26:432-40. [PMID: 32947311 DOI: 10.1097/PPO.0000000000000473] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Alruwaii ZI, Montgomery EA. Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review. Adv Anat Pathol 2022;29:183-93. [PMID: 35470287 DOI: 10.1097/PAP.0000000000000346] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shor J, Churrango G, Hosseini N, Marshall C. Management of microscopic colitis: challenges and solutions. Clin Exp Gastroenterol 2019;12:111-20. [PMID: 30881078 DOI: 10.2147/CEG.S165047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
34 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]